EMA recommendation for 2022-2023 seasonal flu vaccine composition
The European Medicines Agency (EMA) has issued the recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for... Read More
Aurobindo Pharma acquires Veritaz Healthcare
Aurobindo Pharma Ltd has announced the acquisition of the domestic formulation business of Veritaz Healthcare for a consideration of Rs. 171 crore... Read More
Sun Pharma to launch Vortioxetine in India
Sun Pharma has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (“Lundbeck”) to market and distribute its own version... Read More
what is meaning of clinically significant endpoint?
Clinically Significant Endpoints are defined as the desired result which determine that treatment is worked. In other word, it is the clinical... Read More
US FDA grants Breakthrough Therapy Designation for Pfizer’s RSVpreF
Posted on25 Mar 2022
Comments0
Pfizer Inc. announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the US Food... Read More
Is HEOR and Market Access is same?
HEOR and market access are the two separate domain or functional area within pharmaceutical organization. But they work for the same or... Read More
Symbicort 1st generic Approval by USFDA
15th of March, 2022, the U.S. Food and Drug Administration approved the first generic of Symbicort, by Mylan Pharmaceuticals. Symbicort is the... Read More
Case Study : Vimpat patent expired on 17th of March, 2022 and generic entry
It’s all happening now. Finally Vimpat (Lancosamide) patent is expired on 17th of March. And dozens of generics approved on 17th of... Read More
Case Study : US FDA approval of Marinus Pharma’s Ztalmy
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the US Food... Read More
Lynk Pharma, Simcere licensing deal for development of novel JAK1 inhibitor LNK01001 in China
Lynk Pharmaceuticals Co., Ltd. and Simcere announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.... Read More